Home > Healthcare > Medical Devices > Diagnostic Devices > Non-Invasive Prenatal Testing Market
Non-Invasive Prenatal Testing Market Size
- Report ID: GMI10245
- Published Date: Jul 2024
- Report Format: PDF
Non-Invasive Prenatal Testing Market Size
Non-Invasive Prenatal Testing Market size was valued at USD 4.8 billion in 2023 and is expected to exhibit growth at a CAGR of 12.4% from 2024 to 2032. The high incidence rate of genetic disorders significantly drives growth in the market.
Disorders such as Down syndrome, Edwards syndrome, and Patau syndrome have relatively high prevalence rates. Down syndrome, for instance, is among the most common genetic disorders. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in every 700 babies in the U.S. is born with Down syndrome, equating to about 6,000 babies each year. Parents and healthcare providers seek early and accurate methods for detecting these conditions to make informed decisions about pregnancy management and potential interventions. The high incidence rate of these and other genetic disorders underscores the importance of non-invasive prenatal testing.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Non-Invasive Prenatal Testing Market Size in 2023: | USD 4.8 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 12.4% |
| 2032 Value Projection: | USD 13.6 Billion |
| Historical Data for: | 2021 - 2023 |
| No. of Pages: | 100 |
| Tables, Charts & Figures: | 152 |
| Segments covered: | Product, Technology, Application, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Non-invasive prenatal testing (NIPT) is a prenatal screening technique that evaluates cell-free fetal DNA (cffDNA) circulating in a pregnant woman bloodstream to assess the risk of specific chromosomal abnormalities and genetic disorders in the developing fetus.
Frequently Asked Questions (FAQ) :
Non-Invasive Prenatal Testing Market Scope
